Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16371753 | 1.00 | OPRK1 (0.33) | OPRK1OPRD1ALDH1A1MAPTKMT2A | |
| SCHEMBL16423310 | 0.85 | OPRK1 (0.34) | OPRK1OPRD1ALDH1A1MAPTKMT2A | |
| SCHEMBL16423050 | 0.84 | SLC6A9 (0.38) | OPRK1OPRD1ALDH1A1MAPTKMT2A | |
| SCHEMBL16422676 | 0.84 | SLC6A9 (0.38) | OPRK1OPRD1ALDH1A1MAPTKMT2A | |
| SCHEMBL16385996 | 0.83 | ALK (0.42) | — | |
| SCHEMBL13116882 | 0.83 | SMN1; SMN2 (0.43) | OPRK1OPRD1ALDH1A1KMT2A | |
| SCHEMBL444439 | 0.79 | ALDH1A1 (0.36) | OPRK1OPRD1ALDH1A1KMT2AFAAH | |
| SCHEMBL16423147 | 0.76 | PKLR (0.39) | OPRK1OPRD1ALDH1A1MAPTKMT2A | |
| SCHEMBL2242094 | 0.76 | OPRK1 (0.49) | OPRK1OPRD1ALDH1A1MAPTKMT2A | |
| SCHEMBL2246366 | 0.76 | OPRK1 (0.49) | OPRK1OPRD1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367706-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2166846-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | OPRK1 2993/4885OPRD1 4142/4885ALDH1A1 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.